Please note: The information displayed on this page might be outdated.
Minerva Biotechnologies: Minerva Biotechnologies is a clinical stage biopharmaceutical company focused on developing immunotherapies for cancer and cellular therapies in regenerative medicine. Minerva’s anti-cancer therapeutics target an onco-embryonic growth factor, NME7AB, and the growth factor receptor it activates, MUC1*. This growth factor-growth factor receptor pair drives the growth and metastasis of 75% of solid tumor cancers. NCT04020575 is a first-in-human trial of huMNC2-CAR44, a CAR T therapy targeting MUC1* in metastatic breast cancers in patients with MUC1* reactive tumors. No adverse events attributed to the CAR T treatment. Clinical response has been measured in the majority of patients even though still at sub-clinical dose. IND for 1XX version of this CAR T, which greatly increases persistence and recognition of low antigen density cells will be filed in 2021. License agreement with Memorial Sloan Kettering to target MUC1* with MSK’s (Dr. Michel Sadelain) 1XX CAR technology.
US - New England
Phase l or ll
Immuno-Oncology, Immunotherapy, Oncology
Antibodies, Cell Therapy, Small Molecule
40 Bear Hill Road
Company Participants at Fall Private Company Showcase 2021
- Cynthia Bamdad, CEO
- Ron Axelrod